Download PDF
Diabetologie und Stoffwechsel 2020; 15(03): 225-234
DOI: 10.1055/a-1145-3224
Übersicht

Stationäre Therapie des Typ-2-Diabetes

Inpatient Treatment of type 2 diabetes
Juris J. Meier
  Diabetes-Zentrum Bochum/Hattingen, Katholisches Klinikum Bochum, Klinikum der Ruhr-Universität Bochum
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Der überwiegende Teil der Patienten mit Typ-2-Diabetes kann im ambulanten Umfeld (Hausarztpraxen und Diabetes-Schwerpunktpraxen) adäquat und kosteneffektiv behandelt werden. Dennoch erreichen trotz guter ambulanter Versorgungsstrukturen ca. 20–30 % der Patienten keine zufriedenstellende Blutzuckereinstellung. In derartigen Fällen kann eine stationäre Diabetesbehandlung sinnvoll sein. Die Indikationen für eine stationäre Diabetesbehandlung sind in der Nationalen Versorgungsleitlinie Diabetes dargelegt. Besondere Elemente einer stationären Diabetesbehandlung können neben spezifischen Ernährungsinterventionen (z. B. Entlastungstage) spezialisierte Schulungsprogramme, individualisierte Bewegungstherapie ebenso wie eine Anpassung der Insulintherapie bis hin zur intravenösen Insulinbehandlung sein. Eine psychosomatische Mitbetreuung der Patienten erscheint in einer spezialisierten Diabetesbehandlungseinrichtung von essenzieller Bedeutung. Durch die Kombination aus derartigen intensiven Therapiestrategien, einer praktischen Anleitung zur Lebensstilintervention und gruppendynamischen Effekten kann bei vielen Patienten im stationären Rahmen eine deutliche und nachhaltige Verbesserung der Blutzuckereinstellung erzielt werden. Leider ist der Fortbestand derartiger Behandlungseinrichtungen durch die zunehmende Ökonomisierung im Gesundheitssystem und den politisch forcierten Abbau stationärer Versorgungsstrukturen akut gefährdet.

Abstract

The majority of patients with type 2 diabetes can be treated adequately and cost-effectively in outpatient care centers (i. e. by general practitioners or in specialized diabetes outpatient centers). Nevertheless, around 20–30 % of patients do not achieve adequate glycaemic control in those outpatient structures. In such cases inpatient treatment aiming to optimize glycaemic control can be a suitable option. The indications for inpatient treatment of patients with diabetes have been outlined in the national diabetes guideline (“Nationale Versorgungsleitline”). Inpatient care for patients with type 2 diabetes may include specific dietary interventions (e. g. vegetable or oat meal days), specialized training programs, individualized physical therapy as well as the adjustment of insulin therapy, sometimes including transient periods of intravenous insulin therapy. Psychosomatic counselling is a crucial element of inpatient diabetes treatment. Through the combination of intensive pharmacological approaches, practical enforcement of lifestyle intervention and the close interaction amongst affected patients, marked and persistent improvements in glycaemic control can be achieved in a large number of patients undergoing inpatient treatment. Unfortunately, the survival of such inpatients diabetes centers is endangered by the unfavorable reimbursement system and the pressure by politicians and health insurance companies to reduce inpatient treatment capacities.

Schlüsselwörter

Diabetestherapie - Krankenhaus - Insulintherapie - Typ-2-Diabetes

Key words

diabetes treatment - hospital - insulin therapy - type 2 diabetes


Publication History

Received: 21 January 2020

Accepted: 23 March 2020

Article published online:
17 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Meier JJ. Treatment of type 2 diabetes. Internist (Berl) 2016; 57: 153-165
    CrossrefPubMedGoogle Scholar
  • 2 Nauck MA, Meier JJ. Diabetes: Incretin mimetics and insulin – closing the gap to normoglycaemia. Nat Rev Endocrinol 2016; 12: 689-690
    CrossrefPubMedGoogle Scholar
  • 3 Stark Casagrande S, Fradkin JE, Saydah SH. et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 2013; 36: 2271-2279
    CrossrefPubMedGoogle Scholar
  • 4 Tofe S, Arguelles I, Mena E. et al. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol Diabetes Metab 2019; 2: e00051
    PubMedGoogle Scholar
  • 5 Alatorre C, Fernandez Lando L, Yu M. et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab 2017; 19: 953-961
    CrossrefPubMedGoogle Scholar
  • 6 Bell KF, Cappell K, Liang M. et al. Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas. Am Health Drug Benefits 2017; 10: 165-174
    PubMedGoogle Scholar
  • 7 Rathmann W, Kostev K, Gruenberger JB. et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013; 15: 55-61
    CrossrefPubMedGoogle Scholar
  • 8 Holman RR, Farmer AJ, Davies MJ. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747
    CrossrefPubMedGoogle Scholar
  • 9 Laugesen E, Ostergaard JA, Leslie RD. et al. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med 2015; 32: 843-852
    CrossrefPubMedGoogle Scholar
  • 10 Anderson RJ, Freedland KE, Clouse RE. et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001; 24: 1069-1078
    CrossrefPubMedGoogle Scholar
  • 11 Lyra ESNM, Lam MP, Soares CN. et al. Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. Front Psychiatry 2019; 10: 57
    PubMedGoogle Scholar
  • 12 Smith KJ, Beland M, Clyde M. et al. Association of diabetes with anxiety: a systematic review and meta-analysis. J Psychosom Res 2013; 74: 89-99
    CrossrefPubMedGoogle Scholar
  • 13 Berard L, Bonnemaire M, Mical M. et al. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey. Diabetes Obes Metab 2018; 20: 301-308
    CrossrefPubMedGoogle Scholar
  • 14 Munsch S, Herpertz S. Eating disorders associated with obesity and diabetes. Nervenarzt 2011; 82: 1125-1132
    CrossrefPubMedGoogle Scholar
  • 15 Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med 2017; 15: 131
    CrossrefPubMedGoogle Scholar
  • 16 Gupta L, Khandelwal D, Lal PR. et al. Factors Determining the Success of Therapeutic Lifestyle Interventions in Diabetes – Role of Partner and Family Support. Eur Endocrinol 2019; 15: 18-24
    PubMedGoogle Scholar
  • 17 Petrak F, Meier JJ, Albus C. et al. Motivation und Diabetes – Zeit für einen Paradigmenwechsel?. Diabetologie 2019; 14: 193-23
    Article in Thieme ConnectGoogle Scholar
  • 18 Dong Y, Gao W, Zhang L. et al. Patient characteristics related to metabolic disorders and chronic complications in type 2 diabetes mellitus patients hospitalized at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in China. Diab Vasc Dis Res 2017; 14: 24-32
    CrossrefPubMedGoogle Scholar
  • 19 Balcou-Debussche M, Debussche X. Hospitalization for type 2 diabetes: the effects of the suspension of reality on patientsʼ subsequent management of their condition. Qual Health Res 2009; 19: 1100-1115
    CrossrefPubMedGoogle Scholar
  • 20 Ayhan D. Stationäre Diabetestherapie zur glykämischen Kontrolle beim Typ 2-Diabetes – Effizienz nicht-medikamentöser Maßnahmen. Dissertationsschrift. Heinrich Heine Universität Düsseldorf; 2007
    PubMedGoogle Scholar
  • 21 von Noorden C. Die Haferkur Die Zuckerkrankheit und ihre Behandlung. Verlag von August Hirschwald; 1910: 312-321
    Google Scholar
  • 22 Lammert A, Kratzsch J, Selhorst J. et al. Clinical benefit of a short term dietary oatmeal intervention in patients with type 2 diabetes and severe insulin resistance: a pilot study. Exp Clin Endocrinol Diabetes 2008; 116: 132-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Delgado G, Kleber ME, Kramer BK. et al. Dietary Intervention with Oatmeal in Patients with uncontrolled Type 2 Diabetes Mellitus – A Crossover Study. Exp Clin Endocrinol Diabetes 2019; 127: 623-629
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Hou Q, Li Y, Li L. et al. The Metabolic Effects of Oats Intake in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nutrients 2015; 7: 10369-10387
    CrossrefPubMedGoogle Scholar
  • 25 Kovatcheva-Datchary P, Nilsson A, Akrami R. et al. Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella. Cell Metab 2015; 22: 971-982
    CrossrefPubMedGoogle Scholar
  • 26 Shen XL, Zhao T, Zhou Y. et al Effect of Oat beta-Glucan Intake on Glycaemic Control and Insulin Sensitivity of Diabetic Patients: A Meta-Analysis of Randomized Controlled Trials. Nutrients 2016; 8 (01) pii: E39 . doi: 10.3390/nu8010039
    CrossrefPubMedGoogle Scholar
  • 27 Weickert MO, Mohlig M, Schofl C. et al. Cereal fiber improves whole-body insulin sensitivity in overweight and obese women. Diabetes Care 2006; 29: 775-780
    CrossrefPubMedGoogle Scholar
  • 28 Lim EL, Hollingsworth KG, Aribisala BS. et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506-2514
    CrossrefPubMedGoogle Scholar
  • 29 Steven S, Hollingsworth KG, Al-Mrabeh A. et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care 2016; 39: 808-815
    CrossrefPubMedGoogle Scholar
  • 30 Lean ME, Leslie WS, Barnes AC. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541-551
    CrossrefPubMedGoogle Scholar
  • 31 Kirk E, Reeds DN, Finck BN. et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560
    CrossrefPubMedGoogle Scholar
  • 32 Gustafsson K, Asp NG, Hagander B. et al. Satiety effects of spinach in mixed meals: comparison with other vegetables. Int J Food Sci Nutr 1995; 46: 327-334
    CrossrefPubMedGoogle Scholar
  • 33 Rolls BJ, Roe LS, Meengs JS. Salad and satiety: energy density and portion size of a first-course salad affect energy intake at lunch. J Am Diet Assoc 2004; 104: 1570-1576
    CrossrefPubMedGoogle Scholar
  • 34 Roe LS, Meengs JS, Rolls BJ. Salad and satiety. The effect of timing of salad consumption on meal energy intake. Appetite 2012; 58: 242-248
    CrossrefPubMedGoogle Scholar
  • 35 Guess ND. Dietary Interventions for the Prevention of Type 2 Diabetes in High-Risk Groups: Current State of Evidence and Future Research Needs. Nutrients 2018; 10: 1-13
    CrossrefPubMedGoogle Scholar
  • 36 Desalvo DJ, Greenberg LW, Henderson CL. et al. A learner-centered diabetes management curriculum: reducing resident errors on an inpatient diabetes pathway. Diabetes Care 2012; 35: 2188-2193
    CrossrefPubMedGoogle Scholar
  • 37 Shai I, Schwarzfuchs D, Henkin Y. et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359: 229-241
    CrossrefPubMedGoogle Scholar
  • 38 Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med 2013; 369: 676-677
    PubMedGoogle Scholar
  • 39 Hayes D, Angove MJ, Tucci J. et al. Walnuts (Juglans regia) Chemical Composition and Research in Human Health. Crit Rev Food Sci Nutr 2016; 56: 1231-1241
    CrossrefPubMedGoogle Scholar
  • 40 Rock CL, Flatt SW, Barkai HS. et al. Walnut consumption in a weight reduction intervention: effects on body weight, biological measures, blood pressure and satiety. Nutr J 2017; 16: 76
    CrossrefPubMedGoogle Scholar
  • 41 Farr OM, Tuccinardi D, Upadhyay J. et al. Walnut consumption increases activation of the insula to highly desirable food cues: A randomized, double-blind, placebo-controlled, cross-over fMRI study. Diabetes Obes Metab 2018; 20: 173-177
    CrossrefPubMedGoogle Scholar
  • 42 Chen ZP, Stephens TJ, Murthy S. et al. Effect of exercise intensity on skeletal muscle AMPK signaling in humans. Diabetes 2003; 52: 2205-2212
    CrossrefPubMedGoogle Scholar
  • 43 Mackenzie R, Maxwell N, Castle P. et al. Intermittent exercise with and without hypoxia improves insulin sensitivity in individuals with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: E546-E555
    CrossrefPubMedGoogle Scholar
  • 44 Wen CP, Wai JP, Tsai MK. et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011; 378: 1244-1253
    CrossrefPubMedGoogle Scholar
  • 45 Villareal DT, Aguirre L, Gurney AB. et al. Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. N Engl J Med 2017; 376: 1943-1955
    CrossrefPubMedGoogle Scholar
  • 46 Brownrigg JR, Hughes CO, Burleigh D. et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016; 4: 588-597
    CrossrefPubMedGoogle Scholar
  • 47 Mendes R, Sousa N, Almeida A. et al. Exercise prescription for patients with type 2 diabetes-a synthesis of international recommendations: narrative review. Br J Sports Med 2016; 50: 1379-1381
    CrossrefPubMedGoogle Scholar
  • 48 Veronese N, Cooper C, Reginster JY. et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 49: 9-19
    CrossrefPubMedGoogle Scholar
  • 49 Ziegler D, Papanas N, Vinik AI. et al. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol 2014; 126: 3-22
    CrossrefPubMedGoogle Scholar
  • 50 Fritsche A, Stefan N, Haring H. et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134: 729-736
    CrossrefPubMedGoogle Scholar
  • 51 Umpierrez GE, Hellman R, Korytkowski MT. et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 16-38
    CrossrefPubMedGoogle Scholar
  • 52 McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am 2012; 41: 175-201
    CrossrefPubMedGoogle Scholar
  • 53 Buchholz C, Kahle M, Meier JJ. et al. Clinical predictors of the need for further treatment escalation in patients with type 2 diabetes on basal insulin therapy. Exp Clin Endocrinol Diabetes 2019; 127: 663-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Haase M, Kahle M, Janert M. et al. Basal rate tests (24-hour fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial. Diabetes Obes Metab 2017; 19: 783-790
    CrossrefPubMedGoogle Scholar
  • 55 Biesenbach G, Grafinger P, Raml A. Improvement of glycemic control after a 3–5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. Wien Klin Wochenschr 2006; 118: 543-548
    CrossrefPubMedGoogle Scholar
  • 56 Pouwels MJ, Tack CJ, Hermus AR. et al. Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. Diabet Med 2003; 20: 76-79
    CrossrefPubMedGoogle Scholar
  • 57 Augustin-Pascalis I, Richard JL, Rodier M. et al. Secondary failure of oral antidiabetics. Value of intravenous insulin infusions. Diabete Metab 1986; 12: 1-5
    PubMedGoogle Scholar
  • 58 Dandona P, Foster M, Healey F. et al. Low-dose insulin infusions in diabetic patients with high insulin requirements. Lancet 1978; 2: 283-285
    PubMedGoogle Scholar
  • 59 Laedtke T, Kjems L, Porksen N. et al. Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 2000; 279: E520-E528
    CrossrefPubMedGoogle Scholar
  • 60 Rossetti L, Giaccari A, DeFronzo R. Glucose toxicity. Diabetes Care 1990; 13: 610-630
    CrossrefPubMedGoogle Scholar
  • 61 Lengeling HF, Landgraf R, Joost HG. Indikationen für eine stationäre Einweisung. Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft. Diabetologie und Stoffwechsel 2002
    PubMedGoogle Scholar
  • 62 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung (1st edition, Version 3. 2014). 1–251
    Google Scholar
  • 63 Umpierrez GE, Pasquel FJ. Management of Inpatient Hyperglycemia and Diabetes in Older Adults. Diabetes Care 2017; 40: 509-517
    CrossrefPubMedGoogle Scholar
  • 64 Jacobs E, Hoyer A, Brinks R. et al. Healthcare costs of Type 2 diabetes in Germany. Diabet Med 2017; 34: 855-861
    CrossrefPubMedGoogle Scholar